Cagrilintide
Metabolic
ABOUT
Cagrilintide is a long-acting amylin analogue studied in randomised weight-management trials. A phase 2 dose-finding trial reported greater mean weight reduction than placebo in its selected study population.
EVIDENCE OVERVIEW
Early human findings, not yet confirmed
WHAT THIS MEANS
Potential. Review the research and limitations before relying on this record.
IDENTITY
HALF-LIFE
HOW IT IS THOUGHT TO WORK
Cagrilintide is a long-acting amylin analogue, acylated for albumin binding. Amylin is co-secreted with insulin and acts on calcitonin and amylin receptors in the hindbrain to promote satiation and slow gastric emptying - a mechanism distinct from and complementary to GLP-1, which is why it is developed in combination with semaglutide as CagriSema rather than alone.
PHARMACOKINETICS
Half-life of 159 to 195 hours in a phase 1b combination study, supporting once-weekly dosing.
REVIEW
PUBLISHED PAIR RECORDS
with Semaglutide
Directly studied co-administration (CagriSema)Cagrilintide plus semaglutide has been studied as a fixed-dose investigational combination in randomised clinical trials. This is evidence that the exact pair has been co-administered under trial monitoring; it is not a general instruction to combine independently sourced products or a safety conclusion for other preparations.
Reviewed 19 Aug 2026with Tirzepatide
Overlapping incretin-pathway activityTirzepatide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Retatrutide
Overlapping incretin-pathway activityRetatrutide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Survodutide
Overlapping incretin-pathway activitySurvodutide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Mazdutide
Overlapping incretin-pathway activityMazdutide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Native GIP
Overlapping incretin-pathway activityCagrilintide and Native GIP both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. Both members of this pair are investigational rather than approved, so labelled combination data do not exist for either. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with MK-677
Opposing effects on glucose regulationMK-677 raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Cagrilintide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Tesamorelin
Opposing effects on glucose regulationTesamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Cagrilintide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with CJC-1295 with DAC
Opposing effects on glucose regulationCJC-1295 with DAC raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Cagrilintide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Sermorelin
Opposing effects on glucose regulationSermorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Cagrilintide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Ipamorelin
Opposing effects on glucose regulationIpamorelin raises growth-hormone exposure, and growth hormone is a counter-regulatory hormone: controlled human studies show GH administration impairs insulin-stimulated glucose uptake and deteriorates glucose tolerance through increased lipolysis, with chronic GH excess producing insulin resistance. Cagrilintide acts in the opposite direction on glycaemic control. Trials of the oral secretagogue MK-677 specifically report raised fasting glucose and impaired glucose tolerance. The combined effect on blood glucose is therefore not predictable from either agent alone and warrants monitoring rather than assumption. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with PT-141
Additive delay of gastric emptyingBremelanotide (PT-141) labelling states that it slows gastric emptying and may reduce the rate and extent of absorption of concomitantly administered oral medicines - patients are advised to avoid it alongside oral drugs that depend on threshold concentrations, and to avoid oral naltrexone products entirely because exposure is significantly decreased. Approved GLP-1 labelling carries the same gastric-emptying caution. Scheduling Cagrilintide alongside PT-141 therefore stacks two agents that independently delay gastric emptying, which matters most for any oral medicine taken in the same window. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 19 Aug 2026with Liraglutide
Overlapping incretin-pathway activityLiraglutide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Exenatide
Overlapping incretin-pathway activityExenatide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Dulaglutide
Overlapping incretin-pathway activityDulaglutide and Cagrilintide both act on incretin or amylin-family receptor pathways involved in glycaemic control, appetite and gastric emptying. Approved GLP-1 product labelling states that coadministration with another GLP-1 receptor agonist is not recommended, that these agents delay gastric emptying and may affect absorption of concomitantly administered oral medicines, and that combination with insulin or an insulin secretagogue increases hypoglycaemia risk. One member of this pair is an approved prescription product carrying that labelling; the other is investigational, so its combination data are incomplete. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Pramlintide
Same receptor class: overlapping amylin-receptor activityPramlintide and cagrilintide are both amylin analogues acting on calcitonin/amylin receptor complexes, so they engage the same receptor population rather than adding a second mechanism. Both slow gastric emptying and promote satiation. Pramlintide is an approved product whose labelling carries a boxed warning for severe hypoglycaemia alongside insulin and states it is not recommended with other drugs that alter gastrointestinal motility; cagrilintide is investigational and has been studied in combination with semaglutide rather than with another amylin analogue. No study has characterised two amylin analogues given together. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with Teduglutide
Opposing effects on intestinal absorptionTeduglutide is a GLP-2 analogue that increases villus height and crypt depth, enlarging absorptive surface area; its labelling records a potential for increased absorption of concomitant oral medicines and advises monitoring where a drug is titrated or has a narrow therapeutic index, since the oral drug may need its dose reduced. Cagrilintide works in the opposite direction on the same variable - amylin-analogue labelling and pharmacology describe delayed gastric emptying, which slows the rate at which an oral medicine reaches the small intestine. One agent is enlarging the absorptive surface while the other is changing the timing of delivery to it, so the net effect on any co-administered oral medicine is not predictable from either alone. The metabolic agent in this pair is investigational, so no labelled combination guidance exists for it. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 21 Aug 2026with CagriSema
Same substance taken twice: blend already contains this compoundCagriSema already contains Cagrilintide at 2.4 mg per vial. Scheduling the standalone compound alongside the blend means taking it twice from two sources, and the blend's other components come with it whether or not they are wanted at that moment. This is the one exposure risk a blend creates that its individual parts do not, and it is arithmetic rather than pharmacology - the combined amount is whatever the two products add up to. Where a blend's ratio is fixed by the manufacturer, the only way to change one component's dose is to add or remove the whole vial. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 / Ipamorelin blend
Inherited from a component of this blendCJC-1295 / Ipamorelin blend contains Ipamorelin, and the catalogue holds a curated pair record between that component and Cagrilintide: Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with CJC-1295 with DAC / Ipamorelin blend
Inherited from a component of this blendCJC-1295 with DAC / Ipamorelin blend contains CJC-1295 with DAC and Ipamorelin, and the catalogue holds a curated pair record between those components and Cagrilintide: CJC-1295 with DAC (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Sermorelin / Ipamorelin blend
Inherited from a component of this blendSermorelin / Ipamorelin blend contains Sermorelin and Ipamorelin, and the catalogue holds a curated pair record between those components and Cagrilintide: Sermorelin (opposing effects on glucose regulation); Ipamorelin (opposing effects on glucose regulation). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026with Kyinsu
Inherited from a component of this blendKyinsu contains Semaglutide, and the catalogue holds a curated pair record between that component and Cagrilintide: Semaglutide (directly studied co-administration (cagrisema)). Taking the blend therefore carries the same consideration as taking that component on its own, with the difference that a fixed-ratio vial cannot be adjusted independently of the rest of its contents. The evidence and citations here are the component record's; nothing has been studied about the blend itself. Peppy reports curated pharmacology, not a safety verdict. A prescriber or pharmacist should review any intended combination.
Reviewed 25 Aug 2026HUMAN EVIDENCE
Investigational and not approved. Development is primarily as the fixed combination CagriSema (cagrilintide plus semaglutide), where REDEFINE-1 reported about 20.4% mean weight loss - a result which does not separate the contribution of cagrilintide from that of semaglutide. Evidence for cagrilintide as a single agent is thinner than the attention it receives.
REPORTED EFFECTS
Gastrointestinal adverse effects predominate in the combination trials, consistent with both components. No standalone label exists, so there is no regulator-verified adverse-reaction table for cagrilintide alone. No regulator has approved this substance for the use described here, so there is no label-verified dose, purity standard, or safety monitoring requirement behind it.
RESEARCH LIMITATIONS
Trial findings are population-, formulation-, and protocol-specific. This is not a prescribing or combination recommendation; current regulatory status and product labelling must be checked locally.
CURATED SOURCES · 2